Combination stem cell therapy for the treatment of severe limb ischemia: safety and efficacy analysis

The infusion of a source of endothelial progenitors (EPCs) to limb ischemia (LB) patients has been used to increase angiogenesis. Because the formation of new blood vessels involves, in addition to EPCs, other cells and angiogenic regulators, we postulate that a combination cell therapy including EP...

Full description

Saved in:
Bibliographic Details
Published inAngiology Vol. 61; no. 6; p. 551
Main Authors Lasala, Gabriel P, Silva, Jose A, Gardner, Philip A, Minguell, Jose J
Format Journal Article
LanguageEnglish
Published United States 01.08.2010
Subjects
Adult
Aged
Angiogenesis Inducing Agents - therapeutic use
Angiography, Digital Subtraction
Ankle Brachial Index
Female
Flow Cytometry
Humans
Ischemia - diagnostic imaging
Ischemia - therapy
Leg - blood supply
Leg - diagnostic imaging
Male
Middle Aged
Neovascularization, Physiologic
Quality of Life
Radionuclide Imaging
Stem Cell Transplantation
Transplantation, Autologous
Treatment Outcome
Walking - physiology
Online AccessGet more information

Cover

More Information
Summary:The infusion of a source of endothelial progenitors (EPCs) to limb ischemia (LB) patients has been used to increase angiogenesis. Because the formation of new blood vessels involves, in addition to EPCs, other cells and angiogenic regulators, we postulate that a combination cell therapy including EPCs and mesenchymal stem cells (a source of pericytes progenitors and angiogenic regulators) may represent a preferential stimuli for the development of blood vessels. In this phase I clinical trial, patients with LI were infused with a cell product consisting of autologous bone marrow-derived mononuclear and mesenchymal stem cells. After 10 2 months of follow-up, efficacy assessment demonstrated improvements in walking time, ankle brachial pressure, and quality of life. Concomitantly, angiographic and 99mTc-TF perfusion scintigraphy scores confirmed increased perfusion in the treated limbs. These results show that the use of a combination cell therapy is safe, feasible, and appears effective in patients with LI.
ISSN:1940-1574
DOI:10.1177/0003319710364213